MINOLIRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Minolira, and what generic alternatives are available?
Minolira is a drug marketed by Epi Hlth and is included in one NDA. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in MINOLIRA is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Minolira
A generic version of MINOLIRA was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
Summary for MINOLIRA
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Patent Applications: | 3,003 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MINOLIRA |
| DailyMed Link: | MINOLIRA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MINOLIRA
US Patents and Regulatory Information for MINOLIRA
MINOLIRA is protected by one US patents.
Patents protecting MINOLIRA
Pharmaceutical compositions for minocycline
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epi Hlth | MINOLIRA | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209269-001 | May 8, 2017 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Epi Hlth | MINOLIRA | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209269-002 | May 8, 2017 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MINOLIRA
See the table below for patents covering MINOLIRA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016162754 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
